Page 12 - Read Online

Mason What clinicians should want from scientists

REFERENCES Chen BE, Warde P. Final report of the intergroup randomized study
of combined androgen-deprivation therapy plus radiotherapy versus
androgen-deprivation therapy alone in locally advanced prostate
1 Montie JE, Smith JA. Whitmoreisms: memorable quotes from Willet cancer. J Clin Oncol 2015;33:2143-50.
F. Whitmore, Jr, M.D. Urology 2004;63:207-9. 11. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch
2. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears C, Nordling S, Haggman M, Andersson SO, Spangberg A, Andren
MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, O, Palmgren J, Steineck G, Adami HO, Johansson JE. Radical
Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, prostatectomy or watchful waiting in early prostate cancer. N Engl J
Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury Med 2014;370:932-42.
S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, 12. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S,
Hughes R, Laing R, McKinna F, McLaren DB, O’Sullivan JM, Parikh O, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena
Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL,
J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation
investigators. Addition of docetaxel, zoledronic acid, or both to first-line Trial Study Group. Radical prostatectomy versus observation for
long-term hormone therapy in prostate cancer (STAMPEDE): survival localized prostate cancer. N Engl J Med 2012;367:203-13.
results from an adaptive, multiarm, multistage, platform randomised 13. Nelson WG. Commentary on Huggins and Hodges: “Studies on
controlled trial. Lancet 2016;387:1163-77. prostatic cancer”. Cancer Res 2016;76:186-7.
3. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, 14. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC,
Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, Eheman CR, Papaemmanuil E, Brewer DS, Kallio HML, Hognas G, Annala M,
Ward EM. Annual Report to the Nation on the status of cancer, 1975- Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs
2010, featuring prevalence of comorbidity and impact on survival W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D,
among persons with lung, colorectal, breast, or prostate cancer. Whitaker HC, Group IP, Neal DE, Cooper CS, Eeles RA, Visakorpi T,
Cancer 2014;120:1290-314. Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary
4. EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. history of lethal metastatic prostate cancer. Nature 2015;520:353-7.
Prostate cancer and the John West effect. Eur Urol 2017;72:7-9. 15. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D,
5. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate
P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, or deferred androgen deprivation for patients with prostate cancer
Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt not suitable for local treatment with curative intent: European
D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario Organisation for Research and Treatment of Cancer (EORTC) Trial
DJ, Rowe E, Neal DE; ProtecT Study Group. 10-year outcomes after 30891. J Clin Oncol 2006;24:1868-76.
monitoring, surgery, or radiotherapy for localized prostate cancer. N 16. Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke
Engl J Med 2016;375:1415-24. TM, Knonagel H, Loidl W, Isorna S, Sundaram SK, Collette L;
6. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, EORTC Genitourinary Cancer Group. Differences in time to disease
Blazeby JM, Peters TJ, Holding P, Bonnington S, Lennon T, Bradshaw progression do not predict for cancer-specific survival in patients
L, Cooper D, Herbert P, Howson J, Jones A, Lyons N, Salter E, receiving immediate or deferred androgen-deprivation therapy for
Thompson P, Tidball S, Blaikie J, Gray C, Bollina P, Catto J, Doble prostate cancer: final results of EORTC randomized trial 30891 with
A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell 12 years of follow-up. Eur Urol 2014;66:829-38.
P, Prescott S, Rosario DJ, Rowe E, Davis M, Turner EL, Martin RM, 17. O’Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason
Neal DE; ProtecT Study Group. Patient-reported outcomes after M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. Hormonal
monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor
2016;375:1425-37. abiraterone acetate (CB7630) in patients with prostate cancer. Br J
7. Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner Cancer 2004;90:2317-25.
EL, Mason MD, Metcalfe C, Peters TJ, Martin RM, Neal DE, Hamdy 18. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz
FC; ProtecT Study Group. Active monitoring, radical prostatectomy, P, Wilson EM, French FS. The androgen axis in recurrent prostate
or radiotherapy for localised prostate cancer: study design and cancer. Clin Cancer Res 2004;10:440-8.
diagnostic and baseline results of the ProtecT randomised phase 3 19. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi
trial. Lancet Oncol 2014;15:1109-18. KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P,
8. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth
Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz
Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh
with or without long-term androgen suppression for prostate cancer T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone
with high metastatic risk: 10-year results of an EORTC randomised and increased survival in metastatic prostate cancer. N Engl J Med
study. Lancet Oncol 2010;11:1066-73. 2011;364:1995-2005.
9. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson 20. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN,
P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW,
Prostate Cancer Group Study 7; Swedish Association for Urological Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre
Oncology 3. Endocrine treatment, with or without radiotherapy, P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE;
in locally advanced prostate cancer (SPCG-7/SFUO-3): an open COU-AA-302 Investigators. Abiraterone acetate plus prednisone
randomised phase III trial. Lancet 2009;373:301-8. versus placebo plus prednisone in chemotherapy-naive men with
10. Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, metastatic castration-resistant prostate cancer (COU-AA-302): final
Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson overall survival analysis of a randomised, double-blind, placebo-
G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, controlled phase 3 study. Lancet Oncol 2015;16:152-60.
Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, 21. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN,

276 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ November 17, 2017